Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02489903) enrolled people with cancer who had already received prior treatment. A total of 118 people entered the screening phase in one part of the study, and a further 21 in a later part. Of those, 94 went on to receive a combination of RRx-001 (an experimental drug) plus a standard chemotherapy duo called a "platinum doublet," while 11 received RRx-001 combined with platinum chemotherapy followed by more RRx-001, and 2 received a treatment chosen by their doctor (the "investigator's choice" comparison group). The trial was primarily measuring how long participants lived overall, and also tracked whether tumours shrank or stopped growing. The reported data shows that, for overall survival — meaning the time from joining the trial until death or last check-in — the median (the midpoint figure, where half of participants lived longer and half shorter) was 6.85 months for the main RRx-001 plus chemotherapy group, 7.6 months for the RRx-001 plus platinum then RRx-001 group, and 7.5 months for the investigator's choice group. For the secondary measure of how long disease stayed stable or improved before worsening (progression-free survival), the reported figures were 5.87 months, 6.50 months, and 12 months respectively. The reported data also shows that, in the main RRx-001 plus chemotherapy group, 32 participants had their tumour shrink or disappear (overall response), and 42 participants had their disease either shrink, disappear, or remain stable (disease control). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 33569311) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with one of the following advanced or spreading cancers, confirmed by a lab test: small cell carcinoma (at least 3rd line treatment or platinum-resistant/refractory in 2nd line), a specific type of non-small cell lung cancer with an EGFR mutation (after prior platinum and targeted therapy), certain ovarian, fallopian tube, or related cancers (after prior platinum treatment or with platinum-resistant disease), or a high-grade neuroendocrine carcinoma from any part of the body (after prior chemotherapy).
- Your cancer can be measured on a scan using standard guidelines (RECIST v1.1).
- It has been at least 3 weeks since your last cancer treatment.
- You have previously received a platinum-based chemotherapy for your advanced cancer and either did not respond or relapsed within 6 months.
- You are 18 years of age or older.
- Doctors expect you to live for at least 12 weeks or more.
- You are reasonably well and able to carry out daily activities (confirm with trial site — this is measured using a standard scale called ECOG 0–2).
- Your blood counts, kidney function, and liver function meet certain minimum levels before starting treatment (confirm with trial site for specific numbers).
- You agree to allow the trial team and sponsor to access your past medical records, previous scans, and any stored tumor tissue samples.
- You are able to understand and sign a consent form agreeing to take part.
- If you are a woman who could become pregnant, or a man whose partner could become pregnant, you must agree to use reliable contraception during the trial and for 90 days after finishing treatment.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You are currently taking part in another clinical trial involving an experimental treatment.
- You have cancer that has spread to the brain and is causing symptoms (for example, if you need increasing doses of steroids to manage them).
- You previously had to permanently stop platinum-based chemotherapy because of serious side effects (such as kidney damage, hearing loss, or severe nerve damage).
- You have had a severe allergic reaction to platinum-based drugs (such as carboplatin or cisplatin) or to certain chemotherapy drugs that are used alongside platinum in this trial.
- You have a serious ongoing medical condition that doctors feel would make it too risky for you to participate, such as uncontrolled diabetes, significant heart failure, a heart attack in the past 6 months, severe lung disease, uncontrolled infection, or uncontrolled fluid build-up in the lungs.
- You are pregnant or currently breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Overall Survival
Other options
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.